



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 July 2026
EMA/CVMP/154941/2026
Committee for Veterinary Medicinal Products

Summary of opinion¹ (initial authorisation)

Bexatil

International non-proprietary name (INN): Bexagliflozin

On 16 July 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion², recommending the granting of a marketing authorisation for the veterinary medicinal product Bexatil, tablet, intended for cats. The applicant for this veterinary medicinal product is Elanco GmbH.

Bexatil is a blood glucose lowering medicinal product containing Bexagliflozin (ATCvet code QA10BK08) as the active substance, an inhibitor of sodium-glucose co-transporter 2 (SGLT2). Inhibition of SGLT-2 leads to glucose elimination in the urine resulting in a decrease in elevated blood glucose levels in diabetic cats.

The benefits of Bexatil are the reduction of hyperglycaemia in cats with diabetes mellitus not previously treated with insulin.

The most common side effects are vomiting, diarrhoea or loose stool, urinary tract infection, decreased appetite, anorexia, dehydration, lethargy, weight loss, high pancreatic-specific lipase and elevated blood urea nitrogen (BUN). Diabetic ketoacidosis must be screened for prior to treatment start and monitored during treatment.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Bexatil and therefore recommends the granting of the marketing authorisation.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

